267 related articles for article (PubMed ID: 35259535)
1. Dupilumab Demonstrates Rapid Onset of Response Across Three Type 2 Inflammatory Diseases.
Canonica GW; Bourdin A; Peters AT; Desrosiers M; Bachert C; Weidinger S; Simpson EL; Daizadeh N; Chen Z; Kamat S; Khan AH; Chao J; Graham NMH; Laws E; Rossi AB; Ardeleanu M; Mannent LP; Amin N; Ortiz B; Deniz Y; Djandji M; Rowe PJ
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1515-1526. PubMed ID: 35259535
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
3. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
[TBL] [Abstract][Full Text] [Related]
5. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
Mullol J; Bachert C; Amin N; Desrosiers M; Hellings PW; Han JK; Jankowski R; Vodicka J; Gevaert P; Daizadeh N; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
J Allergy Clin Immunol Pract; 2022 Apr; 10(4):1086-1095.e5. PubMed ID: 34628065
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
7. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial.
Paller AS; Bansal A; Simpson EL; Boguniewicz M; Blauvelt A; Siegfried EC; Guttman-Yassky E; Hultsch T; Chen Z; Mina-Osorio P; Lu Y; Rossi AB; He X; Kamal M; Graham NMH; Pirozzi G; Ruddy M; Eckert L; Gadkari A
Am J Clin Dermatol; 2020 Feb; 21(1):119-131. PubMed ID: 31823222
[TBL] [Abstract][Full Text] [Related]
8. Dupilumab effectiveness for the treatment of patients with concomitant atopic dermatitis and chronic rhinosinusitis with nasal polyposis.
Napolitano M; Maffei M; Patruno C; Leone CA; Di Guida A; Potestio L; Scalvenzi M; Fabbrocini G
Dermatol Ther; 2021 Nov; 34(6):e15120. PubMed ID: 34472171
[TBL] [Abstract][Full Text] [Related]
9. Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds.
Chuang CC; Guillemin I; Bachert C; Lee SE; Hellings PW; Fokkens WJ; Duverger N; Fan C; Daizadeh N; Amin N; Mannent LP; Khan AH; Kamat S
Laryngoscope; 2022 Feb; 132(2):259-264. PubMed ID: 34817082
[TBL] [Abstract][Full Text] [Related]
10. Conjunctivitis in dupilumab clinical trials.
Akinlade B; Guttman-Yassky E; de Bruin-Weller M; Simpson EL; Blauvelt A; Cork MJ; Prens E; Asbell P; Akpek E; Corren J; Bachert C; Hirano I; Weyne J; Korotzer A; Chen Z; Hultsch T; Zhu X; Davis JD; Mannent L; Hamilton JD; Teper A; Staudinger H; Rizova E; Pirozzi G; Graham NMH; Shumel B; Ardeleanu M; Wollenberg A
Br J Dermatol; 2019 Sep; 181(3):459-473. PubMed ID: 30851191
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma.
Laidlaw TM; Bachert C; Amin N; Desrosiers M; Hellings PW; Mullol J; Maspero JF; Gevaert P; Zhang M; Mao X; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
Ann Allergy Asthma Immunol; 2021 May; 126(5):584-592.e1. PubMed ID: 33465455
[TBL] [Abstract][Full Text] [Related]
12. Biologics for chronic rhinosinusitis.
Chong LY; Piromchai P; Sharp S; Snidvongs K; Webster KE; Philpott C; Hopkins C; Burton MJ
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013513. PubMed ID: 33710614
[TBL] [Abstract][Full Text] [Related]
13. Dupilumab treatment induced similar improvements in signs, symptoms, and quality of life in adults with moderate-to-severe atopic dermatitis with baseline Eczema Area and Severity Index Score <24 or ≥24.
Offidani A; Stingeni L; Neri I; Cipriani F; Chen Z; Rossi AB; Lu Y; Moretti D
Ital J Dermatol Venerol; 2022 Feb; 157(1):39-46. PubMed ID: 33878856
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan.
Fujieda S; Matsune S; Takeno S; Asako M; Takeuchi M; Fujita H; Takahashi Y; Amin N; Deniz Y; Rowe P; Mannent L
Laryngoscope; 2021 Jun; 131(6):E1770-E1777. PubMed ID: 33226139
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis.
Peters AT; Wagenmann M; Bernstein JA; Khan AH; Nash S; Jacob-Nara JA; Siddiqui S; Rowe PJ; Deniz Y
Allergy Asthma Proc; 2023 Jul; 44(4):265-274. PubMed ID: 37480206
[No Abstract] [Full Text] [Related]
16. Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics.
Busse WW; Pavord ID; Siddiqui S; Khan AH; Praestgaard A; Nash S; Jacob-Nara JA; Rowe PJ; Deniz Y
J Asthma Allergy; 2023; 16():411-419. PubMed ID: 37096015
[TBL] [Abstract][Full Text] [Related]
17. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
Pelaia C; Benfante A; Busceti MT; Caiaffa MF; Campisi R; Carpagnano GE; Crimi N; D'Amato M; Foschino Barbaro MP; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Pelaia G; Portacci A; Ricciardi L; Scichilone N; Scioscia G; Triggiani M; Valenti G; Vatrella A; Crimi C
Front Immunol; 2023; 14():1121237. PubMed ID: 37063895
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.
Bachert C; Khan AH; Lee SE; Hopkins C; Peters AT; Fokkens W; Praestgaard A; Radwan A; Nash S; Jacob-Nara JA; Deniz Y; Rowe PJ
Int Forum Allergy Rhinol; 2024 Mar; 14(3):668-678. PubMed ID: 37548085
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
Simpson EL; Paller AS; Siegfried EC; Boguniewicz M; Sher L; Gooderham MJ; Beck LA; Guttman-Yassky E; Pariser D; Blauvelt A; Weisman J; Lockshin B; Hultsch T; Zhang Q; Kamal MA; Davis JD; Akinlade B; Staudinger H; Hamilton JD; Graham NMH; Pirozzi G; Gadkari A; Eckert L; Stahl N; Yancopoulos GD; Ruddy M; Bansal A
JAMA Dermatol; 2020 Jan; 156(1):44-56. PubMed ID: 31693077
[TBL] [Abstract][Full Text] [Related]
20. Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies.
Geng B; Bachert C; Busse WW; Gevaert P; Lee SE; Niederman MS; Chen Z; Lu X; Khokhar FA; Kapoor U; Pandit-Abid N; Jacob-Nara JA; Rowe PJ; Deniz Y; Ortiz B
J Allergy Clin Immunol Pract; 2022 Mar; 10(3):732-741. PubMed ID: 34954123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]